AbbVie's Upadacitinib (ABT-494) Meets Primary Endpoint in Phase 2b Study in Atopic Dermatitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/23/2026

1. USO
2. META
3. NVDA
4. SPY
5. ONON
6. DCOY
7. MSFT
8. AZO
9. RCL
10. VKTX

Go back to AbbVie's Upadacitinib (ABT-494) Meets Primary Endpoint in Phase 2b Study in Atopic Dermatitis
AbbVie (NYSE: ABBV) Delayed: 265.21 --0 (-0%)
Previous Close $265.21    52 Week High $68.12 
Open $265.21    52 Week Low $50.71 
Day High $265.21    P/E 57.53 
Day Low $265.21    EPS $4.61 
Volume 410